Drug Trial Radar · NCT05102123
PeRiopEratiVE SmokiNg CessaTion Trial
Last checked: Nov 20, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,720
Planned (sponsor's estimate)
Start
Jan 15, 2024
Primary completion
Jul 1, 2026
Study completion Jan 1, 2027
Sponsor
- Lead sponsor
- Population Health Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PREVENT is a multicentre, 2x2 factorial, randomized clinical trial that aims to determine the effect of cytisine versus placebo, as well as the effect of video messaging to support smoking cessation versus standard of care in perioperative patients. This trial aims to investigate the effects of cytisine and text messaging on 6-month continuous abstinence rates. PREVENT will also assess secondary outcomes at 30 days, 56 days and 6 months post-randomization: 7-day point prevalence abstinence, urge to smoke, time to first lapse, time to relapse, number of cigarettes smoking if still smoking, pulmonary complications, vascular complications, wound and infectious complications, stroke, time in hospital and acute hospital care.
Conditions
- Smoking (Tobacco) Addiction
- Smoking Cessation
Interventions
CytisineDrug
Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation
Video MessagingBehavioral
Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Smoking CessationTime frame: 6 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Hamilton General Hospital
Hamilton, Ontario, Canada
Juravinski Cancer Centre
Hamilton, Ontario, Canada
Kingston Health Science Centre with its research institute Kingston General Health Research Institute
Kingston, Ontario, Canada
Lawson Health Research Institute: London Health Sciences Centre Research Inc. and the Lawson Research Institute
London, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.